Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lessened its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 9.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,425 shares of the company’s stock after selling 2,100 shares during the quarter. New York State Common Retirement Fund’s holdings in Arvinas were worth $392,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its position in shares of Arvinas by 18.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after buying an additional 367,343 shares during the last quarter. Baker BROS. Advisors LP acquired a new stake in Arvinas during the third quarter worth about $9,989,000. SG Americas Securities LLC lifted its holdings in Arvinas by 228.8% in the fourth quarter. SG Americas Securities LLC now owns 32,424 shares of the company’s stock worth $622,000 after acquiring an additional 22,564 shares during the last quarter. Wasatch Advisors LP boosted its stake in Arvinas by 58.3% in the third quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock valued at $10,737,000 after acquiring an additional 160,510 shares during the period. Finally, Barclays PLC grew its holdings in shares of Arvinas by 198.9% during the third quarter. Barclays PLC now owns 121,699 shares of the company’s stock valued at $2,998,000 after purchasing an additional 80,984 shares during the last quarter. Institutional investors own 95.19% of the company’s stock.

Arvinas Trading Up 1.8 %

Arvinas stock opened at $16.52 on Wednesday. The company’s 50-day moving average price is $18.32 and its two-hundred day moving average price is $22.59. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -5.96 and a beta of 1.95. Arvinas, Inc. has a 52 week low of $15.53 and a 52 week high of $49.76.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter last year, the firm earned ($2.53) EPS. Research analysts expect that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARVN has been the topic of several recent research reports. Guggenheim reissued a “buy” rating and issued a $57.00 price target on shares of Arvinas in a report on Wednesday, February 12th. Barclays cut their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Stifel Nicolaus lowered their price target on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. Wedbush reaffirmed an “outperform” rating and issued a $57.00 price objective on shares of Arvinas in a report on Tuesday, February 11th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $82.00 target price (down previously from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $60.00.

Insider Activity

In related news, CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the transaction, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. This represents a 5.36 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is owned by company insiders.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.